Small Ball Biotech

Every time you're infected by bacteria or a virus, your immune system works to create treatments to defeat it. Molecularly unique to each person, these tiny cells, or antibodies, either destroy these invaders or mark them for other killer cells to track down. Carl Hansen, 46, is geeking out as...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Forbes 2021-02, Vol.204 (1), p.33
1. Verfasser: Knapp, Alex
Format: Magazinearticle
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page 33
container_title Forbes
container_volume 204
creator Knapp, Alex
description Every time you're infected by bacteria or a virus, your immune system works to create treatments to defeat it. Molecularly unique to each person, these tiny cells, or antibodies, either destroy these invaders or mark them for other killer cells to track down. Carl Hansen, 46, is geeking out as he describes the process over Zoom. "We can make 100 trillion different antibodies," he exclaims. "The immune system is spectacular beyond description." If that sounds more like a college professor than the CEO of a $13 billion (market cap) biotech company, there's a reason: Hansen was one--until 2019, when he left to focus on Vancouver-based AbCellera Biologies, cofounded with fellow researchers from the University of British Columbia in 2012. "Universities are very good at testing new ideas and looking for which road might be effective," he says.
format Magazinearticle
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2492705418</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A666098532</galeid><sourcerecordid>A666098532</sourcerecordid><originalsourceid>FETCH-LOGICAL-g134t-13965538d67d0f1b2211b115254893b23e26a9d6a38c7c787cd4762a684493b33</originalsourceid><addsrcrecordid>eNotj01LxDAYhIMoWFcv_gJP4iWQ982br-O6-AULHtRzSNNsrWRbNSn48y2uc5g5zMPAHLEGtXAciNQxa4QAxbUDOmVnpXyIRUDYsMuXfcj56vbPhqmm-H7OTnYhl3Txnyv2dn_3unnk2-eHp816y3uQVDlIp5WSttOmEztoEQFaAIWKrJMtyoQ6uE4HaaOJxprYkdEYtCVaeilX7Oaw-_k9fc2pVL8fSkw5hzFNc_FIDo1QBHZBrw9oH3Lywxinsaaf2oe5FO_XWi9PrZIofwEXg0G0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>magazinearticle</recordtype><pqid>2492705418</pqid></control><display><type>magazinearticle</type><title>Small Ball Biotech</title><source>EBSCOhost Business Source Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Knapp, Alex</creator><creatorcontrib>Knapp, Alex</creatorcontrib><description>Every time you're infected by bacteria or a virus, your immune system works to create treatments to defeat it. Molecularly unique to each person, these tiny cells, or antibodies, either destroy these invaders or mark them for other killer cells to track down. Carl Hansen, 46, is geeking out as he describes the process over Zoom. "We can make 100 trillion different antibodies," he exclaims. "The immune system is spectacular beyond description." If that sounds more like a college professor than the CEO of a $13 billion (market cap) biotech company, there's a reason: Hansen was one--until 2019, when he left to focus on Vancouver-based AbCellera Biologies, cofounded with fellow researchers from the University of British Columbia in 2012. "Universities are very good at testing new ideas and looking for which road might be effective," he says.</description><identifier>ISSN: 0015-6914</identifier><identifier>EISSN: 2609-1445</identifier><language>eng</language><publisher>New York: Forbes LLC</publisher><subject>Antibodies ; Biotechnology industry ; Businesspeople ; Chief executive officers ; Entrepreneurship ; Evaluation ; Hansen, Carl ; Immune system ; Officials and employees ; R&amp;D ; Research &amp; development</subject><ispartof>Forbes, 2021-02, Vol.204 (1), p.33</ispartof><rights>COPYRIGHT 2021 Forbes LLC</rights><rights>Copyright Forbes Feb/Mar 2021</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>780,784</link.rule.ids></links><search><creatorcontrib>Knapp, Alex</creatorcontrib><title>Small Ball Biotech</title><title>Forbes</title><description>Every time you're infected by bacteria or a virus, your immune system works to create treatments to defeat it. Molecularly unique to each person, these tiny cells, or antibodies, either destroy these invaders or mark them for other killer cells to track down. Carl Hansen, 46, is geeking out as he describes the process over Zoom. "We can make 100 trillion different antibodies," he exclaims. "The immune system is spectacular beyond description." If that sounds more like a college professor than the CEO of a $13 billion (market cap) biotech company, there's a reason: Hansen was one--until 2019, when he left to focus on Vancouver-based AbCellera Biologies, cofounded with fellow researchers from the University of British Columbia in 2012. "Universities are very good at testing new ideas and looking for which road might be effective," he says.</description><subject>Antibodies</subject><subject>Biotechnology industry</subject><subject>Businesspeople</subject><subject>Chief executive officers</subject><subject>Entrepreneurship</subject><subject>Evaluation</subject><subject>Hansen, Carl</subject><subject>Immune system</subject><subject>Officials and employees</subject><subject>R&amp;D</subject><subject>Research &amp; development</subject><issn>0015-6914</issn><issn>2609-1445</issn><fulltext>true</fulltext><rsrctype>magazinearticle</rsrctype><creationdate>2021</creationdate><recordtype>magazinearticle</recordtype><sourceid/><recordid>eNotj01LxDAYhIMoWFcv_gJP4iWQ982br-O6-AULHtRzSNNsrWRbNSn48y2uc5g5zMPAHLEGtXAciNQxa4QAxbUDOmVnpXyIRUDYsMuXfcj56vbPhqmm-H7OTnYhl3Txnyv2dn_3unnk2-eHp816y3uQVDlIp5WSttOmEztoEQFaAIWKrJMtyoQ6uE4HaaOJxprYkdEYtCVaeilX7Oaw-_k9fc2pVL8fSkw5hzFNc_FIDo1QBHZBrw9oH3Lywxinsaaf2oe5FO_XWi9PrZIofwEXg0G0</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Knapp, Alex</creator><general>Forbes LLC</general><general>Forbes</general><scope/></search><sort><creationdate>20210201</creationdate><title>Small Ball Biotech</title><author>Knapp, Alex</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g134t-13965538d67d0f1b2211b115254893b23e26a9d6a38c7c787cd4762a684493b33</frbrgroupid><rsrctype>magazinearticle</rsrctype><prefilter>magazinearticle</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies</topic><topic>Biotechnology industry</topic><topic>Businesspeople</topic><topic>Chief executive officers</topic><topic>Entrepreneurship</topic><topic>Evaluation</topic><topic>Hansen, Carl</topic><topic>Immune system</topic><topic>Officials and employees</topic><topic>R&amp;D</topic><topic>Research &amp; development</topic><toplevel>online_resources</toplevel><creatorcontrib>Knapp, Alex</creatorcontrib><jtitle>Forbes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Knapp, Alex</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Small Ball Biotech</atitle><jtitle>Forbes</jtitle><date>2021-02-01</date><risdate>2021</risdate><volume>204</volume><issue>1</issue><spage>33</spage><pages>33-</pages><issn>0015-6914</issn><eissn>2609-1445</eissn><abstract>Every time you're infected by bacteria or a virus, your immune system works to create treatments to defeat it. Molecularly unique to each person, these tiny cells, or antibodies, either destroy these invaders or mark them for other killer cells to track down. Carl Hansen, 46, is geeking out as he describes the process over Zoom. "We can make 100 trillion different antibodies," he exclaims. "The immune system is spectacular beyond description." If that sounds more like a college professor than the CEO of a $13 billion (market cap) biotech company, there's a reason: Hansen was one--until 2019, when he left to focus on Vancouver-based AbCellera Biologies, cofounded with fellow researchers from the University of British Columbia in 2012. "Universities are very good at testing new ideas and looking for which road might be effective," he says.</abstract><cop>New York</cop><pub>Forbes LLC</pub><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0015-6914
ispartof Forbes, 2021-02, Vol.204 (1), p.33
issn 0015-6914
2609-1445
language eng
recordid cdi_proquest_miscellaneous_2492705418
source EBSCOhost Business Source Complete; EZB-FREE-00999 freely available EZB journals
subjects Antibodies
Biotechnology industry
Businesspeople
Chief executive officers
Entrepreneurship
Evaluation
Hansen, Carl
Immune system
Officials and employees
R&D
Research & development
title Small Ball Biotech
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T06%3A11%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Small%20Ball%20Biotech&rft.jtitle=Forbes&rft.au=Knapp,%20Alex&rft.date=2021-02-01&rft.volume=204&rft.issue=1&rft.spage=33&rft.pages=33-&rft.issn=0015-6914&rft.eissn=2609-1445&rft_id=info:doi/&rft_dat=%3Cgale_proqu%3EA666098532%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2492705418&rft_id=info:pmid/&rft_galeid=A666098532&rfr_iscdi=true